Evidence map›Paper›PMID 38272916›Full record

ArticleCell death discovery2024

ERCC1 abundance is an indicator of DNA repair-apoptosis decision upon DNA damage.

Sule Erdemir Sayan, Rahul Sreekumar, Rahul Bhome, Alex Mirnezami, Tamer Yagci, A Emre Sayan

Open access · goldAbstract read
In one paragraph

Article in Cell death discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Sule Erdemir SayanDepartment of Molecular Biology and Genetics, Gebze Technical University, Kocaeli, 41400, Turkey.ORCID http://orcid.org/0000-0002-6147-7983
Rahul SreekumarCancer Sciences Unit, University of Southampton, Southampton General Hospital, Somers Cancer Research Building, Southampton, SO16 6YD, UK.
Rahul BhomeCancer Sciences Unit, University of Southampton, Southampton General Hospital, Somers Cancer Research Building, Southampton, SO16 6YD, UK.
Alex MirnezamiCancer Sciences Unit, University of Southampton, Southampton General Hospital, Somers Cancer Research Building, Southampton, SO16 6YD, UK.
Tamer YagciDepartment of Molecular Biology and Genetics, Gebze Technical University, Kocaeli, 41400, Turkey.
A Emre SayanCancer Sciences Unit, University of Southampton, Southampton General Hospital, Somers Cancer Research Building, Southampton, SO16 6YD, UK. a.e.sayan@soton.ac.uk.ORCID http://orcid.org/0000-0002-5291-1485
Southampton General Hospital · GBGebze Technical University · TR

Funding

Cancer Research UK (CRUK) C28503/A10013RCUK | Medical Research Council (MRC) MR/L017539/1RCUK | Medical Research Council (MRC) MR/R002061/1Wessex Medical Research (Wessex Medical Trust) T07
6 · The paper itself

Abstract

DNA repair is essential for successful propagation of genetic material and fidelity of transcription. Nucleotide excision repair (NER) is one of the earliest DNA repair mechanisms, functionally conserved from bacteria to human. The fact that number of NER genes vary significantly between prokaryotes and metazoans gives the insight that NER proteins have evolved to acquire additional functions to combat challenges associated with a diploid genome, including being involved in the decision between DNA repair and apoptosis. However, no direct association between apoptosis and NER proteins has been shown to date. In this study, we induced apoptosis with a variety of agents, including oxaliplatin, doxorubicin and TRAIL, and observed changes in the abundance and molecular weight of NER complex proteins. Our results showed that XPA, XPC and ERCC1 protein levels change during DNA damage-induced apoptosis. Among these, ERCC1 decrease was observed as a pre-mitochondria depolarisation event which marks the "point of no return" in apoptosis signalling. ERCC1 decrease was due to proteasomal degradation upon lethal doses of oxaliplatin exposure. When ERCC1 protein was stabilised using proteasome inhibitors, the pro-apoptotic activity of oxaliplatin was attenuated. These results explain why clinical trials using proteasome inhibitors and platinum derivatives showed limited efficacy in carcinoma treatment and also the importance of how deep understanding of DNA repair mechanisms can improve cancer therapy.

Identifiers

PMID38272916
PMCPMC10810800
OpenAlexW4391229427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.